Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 6/2008

01-04-2008 | Case Report

Primary hypertrophic osteoarthropathy with myelofibrosis

Authors: Massoud Saghafi, Azita Azarian, Najmeh Nohesara

Published in: Rheumatology International | Issue 6/2008

Login to get access

Abstract

Primary hypertrophic osteoarthropathy or pachydermoperiostosis is a rare congenital disease characterized by clubbing of the fingers, periostitis of the distal long bones, and hypertrophic skin changes (pachydermia) including thick folds in the skin of the face, forehead, scalp and extremities, and also joint pain. Clinical manifestations of this disease generally appear among the young and middle-aged. In this article we report a case of a 43-year-old man with pachydermoperiostosis. His skin and joint manifestations were prominent. He had also anemia, and bone marrow biopsy showed myelofibrosis.
Literature
1.
Touraine A, Solente G, Gole L (1935) Un syndrome osteodermopathique. La pachydermie plicaturee avec pachyperiostose des extremities. Press Med 43:1820–1824
2.
Gilliland BC (2005) Hypertrophic osteoarthropathy and clubbing. In: Kasper DL et al (eds) Harrison’s principles of internal medicine, 16th edn. Mc Graw-Hill, New York, pp 2061–2063
3.
Cooper RG, Freemont AJ, Riley M et al (1992) Bone abnormalities and server arthritis in pachydermoperiostosis. Ann Rheum Dis 51:416–419PubMedCrossRef
4.
Burns T et al (2004) Rook’s text book of dermatology, 7th edn Black well, Oxford, pp 12-72–3
5.
Odom RB, James WD, Berger TG (2000) Andrews diseases of the skin, 9th edn. Saunders, Philadelphia pp 724–726
6.
Altman RD, Tenenbaum J (2005) Hypertrophic osteoarthropathy. In: Harris DE Jr et al (eds) Kelley’s text book of rheumatology, 7th edn. Elsevier, Philadelphia, pp 1748–1753
7.
Matucci-Cerinic M, Lotti T, Jajic I et al (1991) The clinical spectrum of primary hypertrophic osteoarthropathy. Medicine 70:208–214PubMedCrossRef
8.
Resnick D (ed) (2002) Diagnosis of bone and joint disorders, 4th edn. Saunders, Philadelphia, pp 4870–4885
9.
Moschella SL, Hurley HJ (1992) Dermatology, 3rd edn. Saunders. Philadelphia, pp 1362–1364
10.
Martinez-Lavin M, Pineda C, Valdez T et al (1988) Primary hypertrophic osteoarthropathy. Semin Arthritis Rheum 17:156–162PubMedCrossRef
11.
Hedayati H, Barmada R, Skosey JL (1980) Acrolysis in pachydermoperiostosis, primary or idiopathic hypertrophic osteoarthropathy. Arch Intern Med 140:1087PubMedCrossRef
12.
Sega AM, Mackenzie AH (1982) Hypertrophic osteoarthropathy: a ten year retrospective analysis. Semin Arthritis Rheum 12:220CrossRef
13.
Lauter SA, Vasey FB, Huttner I, Osterland Ck (1976) Pachydermoperiotosis: studies on the synoviom. J Rheumatol 5:85
14.
Lam SK, Hui WKK, Ho J et al (1983) Pachydermoperiostosis, hypertrophic gastropathy, and peptic ulcer. Gastroenterology 84:834–839PubMed
15.
Venencie PY, Boffa GA, Delmas PD et al (1988) Pachydermoperiostosis with gastric hypertrophy, anemia, and increased serum bone Gla-protein levels. Arch Dermatol 124:1831–1834PubMedCrossRef
16.
Neiman HL, Gompels BM, Martel W (1974) Pachydermoperiostosis with bone marrow failure and gross extramedullary hematopoiesis. Report of a case Radiology 110:553PubMed
17.
Tanaka H, Maehamaf S, Imanaka F et al (1991) Pachydermoperiostosis with myelofibrosis and anemia: report of a case of anemia of multifactorial causes and its improvement with steroid pulse and iron therapy. Jpn J Med 30:73–80PubMed
18.
Fontenay-Roupie M,Dupuy E, Berrou E et al (1995) Increased proliferation of bone marrow—derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis. Blood 85:3229–3238PubMed
Metadata
Title
Primary hypertrophic osteoarthropathy with myelofibrosis
Authors
Massoud Saghafi
Azita Azarian
Najmeh Nohesara
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0477-4

Other articles of this Issue 6/2008

Rheumatology International 6/2008 Go to the issue

Original Article

The impact of clothing style on bone mineral density among women in Turkey

Original Article

The differentiation of anaemia in rheumatoid arthritis: parameters of iron-deficiency in an Indian rheumatoid arthritis population

Original Article

Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis

Original Article

Celiac disease in a rheumatology unit: a case study

Case Report

A co-occurrence of sarcoidosis and ankylosing spondylitis: a case report

Case Report

Osteoid osteoma of the acetabulum: a case report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits